HUP0401021A2 - Gepiront tartalmazó gyógyászati készítmény orális beadásra - Google Patents

Gepiront tartalmazó gyógyászati készítmény orális beadásra

Info

Publication number
HUP0401021A2
HUP0401021A2 HU0401021A HUP0401021A HUP0401021A2 HU P0401021 A2 HUP0401021 A2 HU P0401021A2 HU 0401021 A HU0401021 A HU 0401021A HU P0401021 A HUP0401021 A HU P0401021A HU P0401021 A2 HUP0401021 A2 HU P0401021A2
Authority
HU
Hungary
Prior art keywords
gepirone
weight
given amount
gepiron
pharmaceutical composition
Prior art date
Application number
HU0401021A
Other languages
English (en)
Inventor
Johannes Gerardus Joseph Egberink
John Francis Engelhart
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of HUP0401021A2 publication Critical patent/HUP0401021A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgya gyógyászati készítmény orális beadásra nyújtottfelszabadulási tulajdonságokkal, amely gepiron-hidroklorid egy adottmennyiségét, egy cellulózos polimer mátrix egy adott mennyiségét ésmirkokristályos cellulóz egy adott mennyiségét tartalmazza, ahol agyógyászatilag elfogadható cellulózos polimer mátrix aránya 70-85tömeg%, a szénhidrát kötőanyag aránya 7-10 tömeg% és a gepiron-hidroklorid aránya 13-21 tömeg%. A készítmény hasznos depresszió vagyrokon központi idegrendszeri rendellenességek kezelésére gepironnal,naponta egyszeri orális készítményként beadva a gepiron nyújtottfelszabadulása céljából. Ó
HU0401021A 2000-12-08 2001-11-30 Gepiront tartalmazó gyógyászati készítmény orális beadásra HUP0401021A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00204388 2000-12-08
PCT/EP2001/014189 WO2002045753A2 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone

Publications (1)

Publication Number Publication Date
HUP0401021A2 true HUP0401021A2 (hu) 2004-09-28

Family

ID=8172397

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401021A HUP0401021A2 (hu) 2000-12-08 2001-11-30 Gepiront tartalmazó gyógyászati készítmény orális beadásra

Country Status (19)

Country Link
EP (1) EP1343504A2 (hu)
JP (1) JP2004517083A (hu)
KR (1) KR20040018314A (hu)
CN (1) CN1479620A (hu)
AR (1) AR031461A1 (hu)
AU (1) AU2002226371A1 (hu)
BR (1) BR0115976A (hu)
CA (1) CA2436692A1 (hu)
CZ (1) CZ20031589A3 (hu)
EC (1) ECSP034627A (hu)
HU (1) HUP0401021A2 (hu)
IL (1) IL155855A0 (hu)
MX (1) MXPA03005099A (hu)
NO (1) NO20032581D0 (hu)
PL (1) PL362445A1 (hu)
RU (1) RU2003120446A (hu)
SK (1) SK6942003A3 (hu)
WO (1) WO2002045753A2 (hu)
ZA (1) ZA200303915B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545469A1 (en) * 2002-09-24 2005-06-29 Akzo Nobel N.V. Method to improve pharmaceutical tablets having a matrix of cellulose ether
CN101076320A (zh) * 2004-11-05 2007-11-21 法布雷－克雷默控股公司 吉哌隆的高剂量延时释放制剂
EP3657966A1 (en) * 2017-07-26 2020-06-03 Abbott Laboratories Nutritional tablets and methods of making the same
CN109745323A (zh) * 2017-11-01 2019-05-14 四川科瑞德制药股份有限公司 氮哌酮类化合物提高副交感神经活性的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
MXPA03005099A (es) 2004-02-12
AU2002226371A1 (en) 2002-06-18
CN1479620A (zh) 2004-03-03
EP1343504A2 (en) 2003-09-17
ZA200303915B (en) 2004-08-20
ECSP034627A (es) 2004-09-28
WO2002045753A3 (en) 2002-08-29
SK6942003A3 (en) 2003-10-07
JP2004517083A (ja) 2004-06-10
WO2002045753A2 (en) 2002-06-13
KR20040018314A (ko) 2004-03-03
RU2003120446A (ru) 2005-02-20
AR031461A1 (es) 2003-09-24
IL155855A0 (en) 2003-12-23
BR0115976A (pt) 2003-12-30
CZ20031589A3 (cs) 2003-11-12
NO20032581L (no) 2003-06-06
PL362445A1 (en) 2004-11-02
CA2436692A1 (en) 2002-06-13
NO20032581D0 (no) 2003-06-06

Similar Documents

Publication Publication Date Title
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
HUP0302897A2 (hu) Kiváló hatású transzdermális terápiás készítmény a Parkinson-kór kezelésére
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
HUP0202497A2 (hu) Orális, hidrodinamikailag szabályozott hatóanyag leadású készítmény
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
JP2007529564A5 (hu)
MX2008006037A (es) Drogas para el sistema nervioso central para administracion una-vez-al-dia.
RU2006137330A (ru) Пероральные матричные композиции, содержащие ликарбазепин
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
HUP0203782A2 (hu) Oxkarbazepint tartalmazó szuszpenzió és alkalmazása
HUP0402178A2 (hu) 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény
BR9810337A (pt) Utilização de um antagonista especìfico dos receptores 5ht2 para a preparação de medicamentos úteis no tratamento da sìndrome de apnéia do sono
HUP0401021A2 (hu) Gepiront tartalmazó gyógyászati készítmény orális beadásra
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
HUP0303178A2 (hu) Eljárások és készítmények gyógyászatilag aktív anyagok ízének csökkentésére
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
EE05098B1 (et) Molsidomiini pikendatud vabanemisega oraalne galeeniline ravimvorm
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.